Pacific Biosc Stock Price, News & Analysis

PacBio (NASDAQ: PACB) reported preliminary Q4 2024 revenue of $39.2 million and full-year 2024 revenue of $154.0 million, representing year-over-year declines of 33% and 23% respectively. The company shipped 23 Revio and 7 Vega sequencing systems in Q4, with instrument revenue at $15.3 million, down from $35.1 million in Q4 2023.

Notable developments include the early launch of the Vega benchtop system and SPRQ chemistry introduction, enabling sub-$500 HiFi genome sequencing on the Revio system. Consumables revenue remained stable at $18.8 million, with Revio achieving approximately $240,000 in annualized pull-through. The company strengthened its balance sheet by restructuring $459 million in convertible notes and ended 2024 with approximately $390 million in cash and investments.

PacBio (NASDAQ: PACB) and Intus Bio have launched GutID, the first commercial gut health test powered by HiFi sequencing technology. The at-home test combines Intus Bio's Titan-1 platform and PacBio's sequencing capabilities to provide comprehensive microbiome analysis with strain-level resolution.

GutID allows users to collect samples at home and receive detailed reports showing bacteria abundance, including both commensals and pathogens, along with a proprietary microbiome health score and personalized wellness recommendations. The test is particularly beneficial for individuals with IBS, IBD, and those focused on longevity.

This breakthrough addresses limitations of previous microbiome tests that offered low resolution and variable results. The microbiome has been linked to various health outcomes, including cancer, autoimmune, neurodegenerative, and chronic diseases. GutID is now available for purchase at www.gutid.com.

PacBio (NASDAQ: PACB) has delivered its first Vega systems to Berry Genomics under an early access agreement from 2022. Berry Genomics will develop targeted assays for carrier, prenatal, and newborn screening programs in China and other markets using the Vega platform.

The company will pursue NMPA regulatory review in China and support additional product registrations in other markets. Berry has committed to purchasing over 50 Vega units as part of the agreement.

Vega, PacBio's first benchtop long-read sequencing platform introduced last year, is designed as a compact, lower-throughput version of their Revio™ system. It offers HiFi technology for high accuracy and quick turnaround time, targeting small to medium-sized laboratories that need efficient genomics equipment with a smaller footprint and price tag.

PacBio (NASDAQ: PACB), a leading developer of high-quality sequencing solutions, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 14, 2025, at 4:30 PM PT (7:30 PM ET) in San Francisco, California.

Interested parties can access a live webcast of the event through PacBio's investors page at investor.pacificbiosciences.com. The presentation recording will remain available for a minimum of 30 days after the event.

PacBio (NASDAQ: PACB), a leading developer of high-quality sequencing solutions, has announced its participation in four major upcoming investor conferences in November and December 2024. The schedule includes appearances at the UBS Global Healthcare Conference in Rancho Palos Verdes, Wolfe Research Healthcare Conference and Piper Sandler Healthcare Conference in New York, and Stephens Annual Investment Conference in Nashville. All presentations will be available via live webcasts on PacBio's investor page, with replays accessible for at least 30 days after each event.

PacBio reported Q3 2024 financial results with revenue of $40.0 million, down from $55.7 million in Q3 2023. Instrument revenue was $16.8 million, including 22 Revio systems sold. The company reported a net loss of $60.7 million ($0.22 per share). Notable developments include the announcement of SPRQ chemistry for Revio, increasing throughput by 33%, and the launch of Vega, a new long-read benchtop sequencer priced at $169,000. Cash position stood at $471.1 million as of September 30, 2024. The company also announced a private convertible note exchange transaction of $459 million.

PacBio announced a private convertible exchange transaction involving $459 million of its 1.50% Convertible Senior Notes due 2028. In exchange, the company will issue $200 million in new 1.50% Convertible Senior Notes due 2029, issue 20,451,570 shares of common stock, and make a $50 million cash payment. The new notes will have an initial conversion rate of 204.5157 shares per $1,000 principal amount, equivalent to approximately $4.89 per share. The transaction is expected to close around November 21, 2024, and will result in no remaining 2028 Notes outstanding.

PacBio (NASDAQ: PACB) has announced the Vega™ system, its first benchtop long-read sequencing platform, priced at $169,000. The system delivers the functionality of the Revio system in a compact, lower-throughput format. Vega offers HiFi technology for accurate sequencing across various applications, including targeted sequencing, RNA sequencing, and small genome sequencing. The system can process 600 full-length RNA samples per year, 9,600 samples using the PureTarget repeat expansion panel, or 200 human genomes. Shipping is planned to begin in Q1 2025.

Volta Labs has joined the PacBio Compatible program, strengthening their partnership to provide automated library preparation solutions for PacBio sequencing customers. The collaboration centers on the Callisto Sample Prep System, which enables automated preparation of PacBio HiFi libraries with minimal hands-on time (less than 30 minutes) and 5.5 hours of walk-away time. The system supports batch sizes from 4-24 reactions and offers high yield at half-scale reactions. Recent data presented at a Genomeweb webinar demonstrated the system's impact on scaling PacBio sequencing operations, particularly benefiting organizations from core labs to biotech companies.